世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

Pleurodynia Treatment Market  Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Diagnosis (Blood test, Culture test, X-ray), By Treatment (Analgesics or Painkillers, Immunoglobulin), By Mode of Administration (Oral, Injections or infusion), By End-User (Hospitals, Pharmacy, Others), By Region & Competition,  2020-2030F

Pleurodynia Treatment Market Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Diagnosis (Blood test, Culture test, X-ray), By Treatment (Analgesics or Painkillers, Immunoglobulin), By Mode of Administration (Oral, Injections or infusion), By End-User (Hospitals, Pharmacy, Others), By Region & Competition, 2020-2030F


Global Pleurodynia Treatment Market was valued at USD 143.55 Million in 2024 and is anticipated to project steady growth in the forecast period with a CAGR of 5.25% through 2030. The Global Pleurod... もっと見る

 

 

出版社 出版年月 電子版価格 納期 ページ数 言語
TechSci Research
テックサイリサーチ
2025年3月28日 US$4,500
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
PDF:2営業日程度 183 英語

 

Summary

Global Pleurodynia Treatment Market was valued at USD 143.55 Million in 2024 and is anticipated to project steady growth in the forecast period with a CAGR of 5.25% through 2030. The Global Pleurodynia Treatment Market represents a rapidly evolving segment within the healthcare industry, driven by advancements in diagnostic technology and increasing disease prevalence. Pleurodynia, commonly referred to as "Devil’s Grip," is a viral infection primarily caused by enteroviruses, notably Coxsackievirus, and is characterized by acute chest pain and myalgia, predominantly affecting children and young adults.
Market growth is underpinned by significant developments in molecular diagnostics, particularly Polymerase Chain Reaction (PCR) and Next-Generation Sequencing (NGS), which have substantially improved diagnostic precision and reduced the time to detection. These innovations enhance early-stage identification and allow for timely intervention, ultimately improving patient outcomes.
However, the market faces considerable challenges, primarily due to the lack of targeted antiviral therapies and diagnostic complexities. The absence of specialized treatment options results in a reliance on symptomatic management, limiting the scope of therapeutic advancements. Furthermore, pleurodynia’s clinical presentation often mimics cardiac and respiratory disorders, leading to frequent misdiagnosis and delayed or inappropriate treatment. Despite these hurdles, the global pleurodynia treatment market is positioned for sustained growth, fueled by rising incidence rates and continued investment in diagnostic research. Addressing treatment gaps and refining diagnostic protocols will be critical to unlocking the market’s full potential and enhancing patient care.
Key Market Drivers
Advancements in Medical Research and Technology
In recent years, the healthcare industry has experienced an unprecedented surge in medical research and technological advancements. These innovations have played a pivotal role in driving the growth of the Global Pleurodynia Treatment Market. Cutting-edge diagnostic tools and therapeutic options have been developed, significantly enhancing the management of pleurodynia.
One notable advancement is the utilization of molecular diagnostic techniques, such as Polymerase Chain Reaction (PCR) tests. These tests have revolutionized the accuracy and speed of pleurodynia diagnosis. By detecting the viral RNA in patient samples, PCR tests provide rapid and precise results, enabling healthcare professionals to initiate treatment promptly. NGS has also emerged as a game-changer in pleurodynia diagnosis and research. This high-throughput sequencing technology allows for the comprehensive analysis of viral genomes, aiding in the understanding of pleurodynia strains and their genetic variations. Such insights are invaluable for the development of targeted treatments.
Key Market Challenges
Limited Awareness and Misdiagnosis
One of the primary challenges hindering the growth of the Global Pleurodynia Treatment Market is the limited awareness among the general population. Pleurodynia, often referred to as "Devil's Grip," is a relatively uncommon viral infection. Many individuals may not recognize its symptoms, which can mimic other, more common ailments. This lack of awareness results in delayed diagnosis and treatment, impacting market growth.
The symptoms of pleurodynia, including severe chest pain and muscle aches, overlap with those of other respiratory and musculoskeletal conditions. Healthcare professionals may misdiagnose pleurodynia as conditions like pneumonia or muscular strain, leading to inappropriate treatment. Accurate and timely diagnosis is crucial for the effective management of pleurodynia, and misdiagnosis can slow down market expansion.
Key Market Trends
Advancements in Diagnostic Technologies
One significant trend in the Global Pleurodynia Treatment Market is the rapid advancement of diagnostic technologies. Molecular diagnostic techniques, such as Polymerase Chain Reaction (PCR) and next-generation sequencing (NGS), have gained prominence. These techniques enable healthcare professionals to detect pleurodynia with higher accuracy and speed by identifying viral RNA in patient samples. The adoption of these cutting-edge diagnostic tools is improving the efficiency of pleurodynia diagnosis and facilitating early treatment initiation.
Another notable trend is the development of point-of-care testing for pleurodynia. Point-of-care tests provide rapid results at the patient's bedside or in outpatient settings. These tests are particularly beneficial in regions with limited access to advanced healthcare facilities. The availability of point-of-care tests is expected to enhance the early detection and management of pleurodynia.
Key Market Players
• Bristol-Myers Squibb Co
• F. Hoffmann-La Roche Ltd
• Pfizer Inc
• Sanofi SA
• Johnson & Johnson
• Merck & Co Inc.
• GlaxoSmithKline PLC
• Reckitt Benckiser PLC
• Bayer AG
• Novartis AG
Report Scope:
In this report, the Global Pleurodynia Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
• Pleurodynia Treatment Market, By Diagnosis:
o Blood test
o Culture test
o X-ray
• Pleurodynia Treatment Market, By Treatment:
o Analgesics or Painkillers
o Immunoglobulin
• Pleurodynia Treatment Market, By Mode of Administration:
o Oral
o Injections or infusion
• Pleurodynia Treatment Market, By End-User:
o Hospitals
o Pharmacy
o Others
• Pleurodynia Treatment Market, By Region:
o North America
§ United States
§ Canada
§ Mexico
o Europe
§ France
§ United Kingdom
§ Italy
§ Germany
§ Spain
o Asia-Pacific
§ China
§ India
§ Japan
§ Australia
§ South Korea
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Pleurodynia Treatment Market.
Available Customizations:
Global Pleurodynia Treatment market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
• Detailed analysis and profiling of additional market players (up to five).


ページTOPに戻る


Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Pleurodynia Treatment Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Diagnosis (Blood test, Culture test, X-ray)
5.2.2. By Treatment (Analgesics or Painkillers, Immunoglobulin)
5.2.3. By Mode of Administration (Oral, Injections or infusion)
5.2.4. By End-User (Hospitals, Pharmacy, Others)
5.2.5. By Region
5.2.6. By Company (2024)
5.3. Market Map
6. North America Pleurodynia Treatment Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Diagnosis
6.2.2. By Treatment
6.2.3. By Mode of Administration
6.2.4. By End User
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Pleurodynia Treatment Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Diagnosis
6.3.1.2.2. By Treatment
6.3.1.2.3. By Mode of Administration
6.3.1.2.4. By End User
6.3.2. Canada Pleurodynia Treatment Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Diagnosis
6.3.2.2.2. By Treatment
6.3.2.2.3. By Mode of Administration
6.3.2.2.4. By End User
6.3.3. Mexico Pleurodynia Treatment Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Diagnosis
6.3.3.2.2. By Treatment
6.3.3.2.3. By Mode of Administration
6.3.3.2.4. By End User
7. Europe Pleurodynia Treatment Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Diagnosis
7.2.2. By Treatment
7.2.3. By Mode of Administration
7.2.4. By End User
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Pleurodynia Treatment Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Diagnosis
7.3.1.2.2. By Treatment
7.3.1.2.3. By Mode of Administration
7.3.1.2.4. By End User
7.3.2. United Kingdom Pleurodynia Treatment Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Diagnosis
7.3.2.2.2. By Treatment
7.3.2.2.3. By Mode of Administration
7.3.2.2.4. By End User
7.3.3. Italy Pleurodynia Treatment Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Diagnosis
7.3.3.2.2. By Treatment
7.3.3.2.3. By Mode of Administration
7.3.3.2.4. By End User
7.3.4. France Pleurodynia Treatment Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Diagnosis
7.3.4.2.2. By Treatment
7.3.4.2.3. By Mode of Administration
7.3.4.2.4. By End User
7.3.5. Spain Pleurodynia Treatment Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Diagnosis
7.3.5.2.2. By Treatment
7.3.5.2.3. By Mode of Administration
7.3.5.2.4. By End User
8. Asia-Pacific Pleurodynia Treatment Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Diagnosis
8.2.2. By Treatment
8.2.3. By Mode of Administration
8.2.4. By End User
8.2.5. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Pleurodynia Treatment Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Diagnosis
8.3.1.2.2. By Treatment
8.3.1.2.3. By Mode of Administration
8.3.1.2.4. By End User
8.3.2. India Pleurodynia Treatment Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Diagnosis
8.3.2.2.2. By Treatment
8.3.2.2.3. By Mode of Administration
8.3.2.2.4. By End User
8.3.3. Japan Pleurodynia Treatment Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Diagnosis
8.3.3.2.2. By Treatment
8.3.3.2.3. By Mode of Administration
8.3.3.2.4. By End User
8.3.4. South Korea Pleurodynia Treatment Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Diagnosis
8.3.4.2.2. By Treatment
8.3.4.2.3. By Mode of Administration
8.3.4.2.4. By End User
8.3.5. Australia Pleurodynia Treatment Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Diagnosis
8.3.5.2.2. By Treatment
8.3.5.2.3. By Mode of Administration
8.3.5.2.4. By End User
9. South America Pleurodynia Treatment Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Diagnosis
9.2.2. By Treatment
9.2.3. By Mode of Administration
9.2.4. By End User
9.2.5. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Pleurodynia Treatment Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Diagnosis
9.3.1.2.2. By Treatment
9.3.1.2.3. By Mode of Administration
9.3.1.2.4. By End User
9.3.2. Argentina Pleurodynia Treatment Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Diagnosis
9.3.2.2.2. By Treatment
9.3.2.2.3. By Mode of Administration
9.3.2.2.4. By End User
9.3.3. Colombia Pleurodynia Treatment Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Diagnosis
9.3.3.2.2. By Treatment
9.3.3.2.3. By Mode of Administration
9.3.3.2.4. By End User
10. Middle East and Africa Pleurodynia Treatment Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Diagnosis
10.2.2. By Treatment
10.2.3. By Mode of Administration
10.2.4. By End User
10.2.5. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Pleurodynia Treatment Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Diagnosis
10.3.1.2.2. By Treatment
10.3.1.2.3. By Mode of Administration
10.3.1.2.4. By End User
10.3.2. Saudi Arabia Pleurodynia Treatment Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Diagnosis
10.3.2.2.2. By Treatment
10.3.2.2.3. By Mode of Administration
10.3.2.2.4. By End User
10.3.3. UAE Pleurodynia Treatment Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Diagnosis
10.3.3.2.2. By Treatment
10.3.3.2.3. By Mode of Administration
10.3.3.2.4. By End User
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions
13. Global Pleurodynia Treatment Market: SWOT Analysis
14. Competitive Landscape
14.1. Bristol-Myers Squibb Co
14.1.1. Business Overview
14.1.2. Product & Service Offerings
14.1.3. Recent Developments
14.1.4. Financials (If Listed)
14.1.5. Key Personnel
14.1.6. SWOT Analysis
14.2. F. Hoffmann-La Roche Ltd
14.3. Pfizer Inc
14.4. Sanofi SA
14.5. Johnson & Johnson
14.6. Merck & Co Inc.
14.7. GlaxoSmithKline PLC
14.8. Reckitt Benckiser PLC
14.9. Bayer AG
14.10.Novartis AG
15. Strategic Recommendations

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(医療)の最新刊レポート

TechSci Research社のヘルスケア分野での最新刊レポート

本レポートと同じKEY WORD(industry)の最新刊レポート


よくあるご質問


TechSci Research社はどのような調査会社ですか?


テックサイリサーチ(TechSci Research)は、カナダ、英国、インドに拠点を持ち、化学、IT、環境、消費財と小売、自動車、エネルギーと発電の市場など、多様な産業や地域を対象とした調査・出版活... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2025/04/08 10:26

148.77 円

163.31 円

192.60 円

ページTOPに戻る